HSCI bridges the gaps in traditional research funding to encourage bold thinking and launch scientific careers.
Through our disease programs, we channel world-class resources, both intellectual and technological, toward some of the most prevalent, devastating diseases for which stem cell research holds promise.
In addition, our seed grants and junior faculty programs provide funding for innovative, early-stage projects in stem cell research. This allows up-and-coming scientists to pursue "high risk/high reward" avenues of research that might be difficult to fund from other sources.
Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D).
HSCI has been breaking down barriers to collaboration in stem cell science since 2004. We provide fertile ground for more than 350research faculty and their labs, across the university’s schools, centers, teaching hospitals, and partner companies, to share knowledge and pursue bold new ideas.
With Harvard as a wellspring of discovery and a strong network that embraces new ways of working, we are better equipped than ever to change human health in ways that will benefit all of society.
A key part of our mission is to move research out of the lab and into the clinic. Since our founding, we have been forging a clear path to translating discoveries into products that benefit patients. Now, we have the flexibility to organize people across institutions and sectors to tackle specific biological problems so we can make a lasting difference in people's lives.